18F-fluorodeoxyglucose	18F-FDG
Antigen presenting cells	APC
Complete Metabolic Response	CMR
Complete response	CR
Computed tomography	CT
Cytotoxic T cells	CTLs
Cytotoxic T-lymphocyte antigen 4	CTLA-4
Gastrointestinal stromal tumors	GIST
Glucose transporter 1	GLUT1
Interferon γ	IFNγ
Interleukine-2	IL-2
Immune checkpoint inhibitor	ICI
Immune-modified RECIST	imRECIST
Immune PERCIST	iPERCIST
Immune RECIST	iRECIST
Immune-related adverse effect	IrAE
Immune-related RECIST	irRECIST
Immune-related response criteria	irRC
Immunotherapy-modified PERCIST up to 5 lesions	imPERCIST5
Non-small cell lung cancer	NSCLC
Major histocompatibility complex	MHC
Magnetic resonance imaging	MRI
Myeloid-derived suppressor cells	MDSC
Partial Metabolic Response	PMR
Partial Response	PR
PET/CT Criteria for early prediction of Response to Immune checkpoint inhibitor Therapy	PECRIT
PET Response Criteria in Solid Tumors	PERCIST
PET Response Evaluation Criteria for Immunotherapy	PERCIMT
Programmed cell death protein-1	PD-1
Programmed cell death protein-1 ligand	PDL-1
Progression disease	PD
Positron emission tomography	PET
Preferred Reporting Items for Systematic Reviews and Meta-Analyses	PRISMA
Response Evaluation Criteria in Solid Tumors	RECIST
Single photon emission computed tomography	SPECT
Stable disease	SD
Standardized uptake value	SUV
Standardized uptake value normalized par lean body mass	SUL
T-cell receptor	TCR
Total lesion glycolysis	TLG
Total metabolic tumor volume	TMTV
Tumor-infiltrating lymphocytes	TILs